Bài phát biểu đầy đủ của Bitcoin 2025 Vance: Tài sản kỹ thuật số là biểu tượng và động lực cho quyền tự do cá nhân của người Mỹ

ADC Therapeutics

company

About

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

  • 251 - 500

Details

Last Funding Type
Series E
Last Funding Money Raised
Fr76M
Industries
Biopharma,Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
251 - 500
Operating Status
Active

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
Fr76M $385M
ADC Therapeutics has raised a total of Fr76M $385M in funding over 2 rounds. Their latest funding was raised on Jun 12, 2019 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 12, 2019 Series E Fr76M 1 Detail
Oct 23, 2017 Series E $200M 1 Detail
Oct 27, 2016 Series D $105M 1 Detail
Sep 2, 2015 Series C $80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
ADC Therapeutics is funded by 1 investors. AstraZeneca are the most recent investors.
Investor Name Lead Investor Funding Round
AstraZeneca Series E